Genmab A/S (GNMSF)
Genmab A/S Statistics
Share Statistics
Genmab A/S has 61.47M shares outstanding. The number of shares has increased by -2.46% in one year.
Shares Outstanding | 61.47M |
Shares Change (YoY) | -2.46% |
Shares Change (QoQ) | 0.04% |
Owned by Institutions (%) | n/a |
Shares Floating | 59.41M |
Failed to Deliver (FTD) Shares | - |
FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 73.03K, so 0.12% of the outstanding shares have been sold short.
Short Interest | 73.03K |
Short % of Shares Out | 0.12% |
Short % of Float | 0.12% |
Short Ratio (days to cover) | 4.35 |
Valuation Ratios
The PE ratio is 12.22 and the forward PE ratio is null. Genmab A/S's PEG ratio is 0.14.
PE Ratio | 12.22 |
Forward PE | n/a |
PS Ratio | 4.45 |
Forward PS | n/a |
PB Ratio | 2.61 |
P/FCF Ratio | 12.84 |
PEG Ratio | 0.14 |
Enterprise Valuation
Genmab A/S has an Enterprise Value (EV) of 87.05B.
EV / Sales | 4.04 |
EV / EBITDA | 8.98 |
EV / EBIT | 11.2 |
EV / FCF | 11.66 |
Financial Position
The company has a current ratio of 5.25, with a Debt / Equity ratio of 0.03.
Current Ratio | 5.25 |
Quick Ratio | 5.24 |
Debt / Equity | 0.03 |
Debt / EBITDA | 0.11 |
Debt / FCF | 0.14 |
Interest Coverage | 55.86 |
Financial Efficiency
Return on Equity is 21.38% and Return on Invested Capital is 14.13%.
Return on Equity | 21.38% |
Return on Assets | 17.12% |
Return on Invested Capital | 14.13% |
Revenue Per Employee | $8.03M |
Profits Per Employee | $2.92M |
Employee Count | 2,682 |
Asset Turnover | 0.47 |
Inventory Turnover | 15.89 |
Taxes
Income Tax | 1.32B |
Effective Tax Rate | 14.4% |
Stock Price Statistics
The stock price has increased by -25.81% in the last 52 weeks. The beta is 0.96, so Genmab A/S's price volatility has been higher than the market average.
Beta | 0.96 |
52-Week Price Change | -25.81% |
50-Day Moving Average | 203.92 |
200-Day Moving Average | 225.61 |
Relative Strength Index (RSI) | 57.79 |
Average Volume (20 Days) | 1.96K |
Income Statement
In the last 12 months, Genmab A/S had revenue of 21.53B and earned 7.84B in profits. Earnings per share was 122.21.
Revenue | 21.53B |
Gross Profit | 20.54B |
Operating Income | 6.7B |
Net Income | 7.84B |
EBITDA | 9.7B |
EBIT | 9.28B |
Earnings Per Share (EPS) | 122.21 |
Balance Sheet
The company has 9.86B in cash and 1.03B in debt, giving a net cash position of 8.83B.
Cash & Cash Equivalents | 9.86B |
Total Debt | 1.03B |
Net Cash | 8.83B |
Retained Earnings | 23.55B |
Total Assets | 45.81B |
Working Capital | 22.55B |
Cash Flow
In the last 12 months, operating cash flow was 7.77B and capital expenditures -304M, giving a free cash flow of 7.47B.
Operating Cash Flow | 7.77B |
Capital Expenditures | -304M |
Free Cash Flow | 7.47B |
FCF Per Share | 116.33 |
Margins
Gross margin is 95.42%, with operating and profit margins of 31.14% and 36.44%.
Gross Margin | 95.42% |
Operating Margin | 31.14% |
Pretax Margin | 42.57% |
Profit Margin | 36.44% |
EBITDA Margin | 45.05% |
EBIT Margin | 31.14% |
FCF Margin | 34.69% |
Dividends & Yields
GNMSF does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | 8.18% |
FCF Yield | 7.79% |
Analyst Forecast
Currently there are no analyst rating for GNMSF.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Scores
Altman Z-Score | 3.14 |
Piotroski F-Score | 5 |